The restriction of parallel trade
HvJ EG, 30 juni 2009, conclusie AG Trstenjak, gevoegde zaken J C-501/06 P, C-513/06 P, C-515/06 P and C-519/06 P, GlaxoSmithKline Services Unlimited, tegen Commissie EU en Commissie EU, EAEPC & Aseprofar tegen GlaxoSmithKline Services Unlimited. (Nederlandse vertaling nog niet beschikbaar).
Mededinging. Parallelimport. Geneesmiddelen.
The purpose of the General Sales Conditions was to restrict parallel trade in GSK’s medicines between Spain and other Member States, in which the Spanish intermediaries were engaging on account of the price differentials between Member States. In GSK’s view, the parallel trade primarily benefits the intermediaries while a restriction of parallel trade is beneficial to the final consumers. GSK argues that the additional resources which it, or the group to which it belongs, (3) obtains through the restriction of parallel trade can be invested by it in the research and development of new medicines.
GSK notified the General Sales Conditions to the Commission. In its decision of 8 May 2001 (4) (‘the contested decision’), the Commission found that the General Sales Conditions infringed Article 81(1) EC and could not be exempted under Article 81(3) EC. Ruling on GSK’s action by judgment of 27 September 2006 in Case T-168/01 (5) (‘the judgment under appeal’), the Court of First Instance upheld the contested decision in so far as the Commission found that the General Sales Conditions infringed Article 81(1) EC, but annulled it in so far as the Commission rejected the request for exemption of the General Sales Conditions under Article 81(3) EC.
By its appeal in Case C-501/06 P, GSK, on the one hand, contests the judgment under appeal in so far as it upheld the Commission’s finding that the General Sales Conditions infringe Article 81(1) EC. On the other hand, the Commission (supported by the Republic of Poland as intervener), the Asociación de exportadores españoles de productos farmacéuticos (‘Aseprofar’) and the European Association of Euro Pharmaceutical Companies (‘EAEPC’) by their appeals in Cases C-513/06 P, C-515/06 P and C-519/06 P, and the Commission and Aseprofar by their cross-appeals in Case C-501/06 P, contest the judgment under appeal in so far as it annulled the Commission’s decision to reject GSK’s request for exemption of the General Sales Conditions under Article 81(3) EC.
(…) 305. The appeals against the judgment under appeal should therefore be dismissed, albeit, as regards GSK’s appeal in Case C-501/06 P, with replacement of the grounds relating to the anti-competitive object of the General Sales Conditions and, as regards the appeals of the Commission, EAEPC and Aseprofar in Cases C-513/06 P, C-515/06 P and C-519/06 P and the cross-appeals of the Commission and Aseprofar in Case C-501/06 P, with replacement of the part of the grounds in which the Court of First Instance distorted the content of the contested decision.
Lees het arrest hier.
